Fate Therapeutics CEO leaves the helm; Biotech seed fund draws $41M;

@FierceBiotech: Fast Company highlights 10 top innovators in biotech. Article | Follow @FierceBiotech

@JohnCFierce: FDA plans to release new biosimilar rules "very soon." Report | Follow @JohnCFierce 

> San Diego-based Fate Therapeutics has announced that CEO Paul Grayson is on his way out. The developer says Grayson is leaving to start a new company; however, it didn't say what the focus of the new venture will be. Fate release

> Investissement Quebec and FIER Partenaires are contributing to a new, $41.25 million biotech investment fund. "We hope this will be a trigger that will lead to a bunch of new companies that will create a critical mass that will then attract the regular venture capitalists," said new seed fund manager Louis Lacasse. Story

> Medivir AB released "further positive results" from the Phase IIb study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1. Medivir release

> Genzyme announced three-year follow-up data from patients enrolled in the Phase II clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint. Genzyme release

> Omeros announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo has been amended to include addiction and compulsive disorders in the field of use. Omeros release

And Finally... About one in nine middle-aged Americans have experienced hearing loss. Story